In situ regulation of DC subsets and T cells mediates tumor regression in mice

Science Translational Medicine

Volumn 1, Issue 8, 2009, Pages

  Ali, Omar A ^a,b,c   Emerich, Dwaine ^b   Dranoff, Glenn ^d,e   Mooney, David J ^a,c  

^a HARVARD UNIVERSITY   (United States)

^b InCytu Inc   (United States)

^c HARVARD UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 12;

ANIMAL; ARTICLE; BIOSYNTHESIS; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; CANCER VACCINES; CPG ISLANDS; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERONS; INTERLEUKIN-12; MICE; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77953720628     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000359     Document Type: Article

References (42)

1. S. A. Rosenberg, J. C. Yang, N. P. Restifo, Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
2. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214-224 (2006).
3. R. M. Steinman, J. Banchereau, Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
4. E. Gilboa, DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007).
5. G. Schuler, B. Schuler-Thurner, R. M. Steinman, The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
6. T. J. Curiel, D. T. Curiel, Tumor immunotherapy: Inching toward the finish line. J. Clin. Invest. 109, 311-312 (2002).
7. S. H. Naik, P. Sathe, H. Y. Park, D. Metcalf, A. I. Proietto, A. Dakic, S. Carotta, M. O'Keeffe, M. Bahlo, A. Papenfuss, J. Y. Kwak, L. Wu, K. Shortman, Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat. Immunol. 8, 1217-1226 (2007).
8. A. O'Garra, G. Trinchieri, Are dendritic cells afraid of commitment? Nat. Immunol. 5, 1206-1208 (2004).
9. A. D'Amico, L. Wu, The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J. Exp. Med. 198, 293-303 (2003).
10. A. M. Krieg, Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117, 1184-1194 (2007).
11. T. Kawai, S. Akira, Innate immune recognition of viral infection. Nat. Immunol. 7, 131-137 (2006).
12. J. J. O'Shea, R. Visconti, Type 1 IFNs and regulation of TH1 responses: Enigmas both resolved and emerge. Nat. Immunol. 1, 17-19 (2000).
13. J. A. Villadangos, P. Schnorrer, Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7, 543-555 (2007).
14. + dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl. Acad. Sci. U.S.A. 103, 10729-10734 (2006).
15. K. Shortman, S. H. Naik, Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 7, 19-30 (2007).
16. J. A. Hamilton, GM-CSF in inflammation and autoimmunity. Trends Immunol. 23, 403-408 (2002).
17. M. C. Dieu, B. Vanbervliet, A. Vicari, J. M. Bridon, E. Oldham, S. Aït-Yahia, F. Brière, A. Zlotnik, S. Lebecque, C. Caux, Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188, 373-386 (1988).
18. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, R. C. Mulligan, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543 (1993).
19. B. Pulendran, J. Banchereau, S. Burkeholder, E. Kraus, E. Guinet, C. Chalouni, D. Caron, C. Maliszewski, J. Davoust, J. Fay, K. Palucka, Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566-572 (2000).
20. O. A. Ali, N. Huebsch, L. Cao, G. Dranoff, D. J. Mooney, Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 8, 151-158 (2009).
21. N. Mach, S. Gillessen, S. B. Wilson, C. Sheehan, M. Mihm, G. Dranoff, Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60, 3239-3246 (2000).
22. high murine dendritic cells in vivo: A comparative analysis with Flt3 ligand. J. Immunol. 165, 49-58 (2000).
23. C. Fonseca, G. Dranoff, Capitalizing on the immunogenicity of dying tumor cells. Clin. Cancer Res. 14, 1603-1608 (2008).
24. J. D. Farrar, H. Asnagli, K. M. Murphy, T helper subset development: Roles of instruction, selection, and transcription. J. Clin. Invest. 109, 431-435 (2002).
25. - DCs induce IL-12-independent Th1 differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. J. Exp. Med. 204, 1525-1531 (2007).
26. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685-1696 (2000).
27. M. Moser, K. M. Murphy, Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1, 199-205 (2000).
28. -/- setting. Immunity 16, 429-439 (2002).
29. V. E. Schijns, B. L. Haagmans, C. M. Wierda, B. Kruithof, I. A. Heijnen, G. Alber, M. C. Horzinek, Mice lacking IL-12 develop polarized Th1 cells during viral infection. J. Immunol. 160, 3958-3964 (1998).
30. J. Magram, J. Sfarra, S. Connaughton, D. Faherty, R. Warrier, D. Carvajal, C. Y. Wu, C. Stewart, U. Sarmiento, M. K. Gately, IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann. N.Y. Acad. Sci. 795, 60-70 (1996).
31. + T cells. J. Exp. Med. 198, 569-580 (2003).
32. Y. Tamura, P. Peng, K. Liu, M. Daou, P. K. Srivastava, Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117-120 (1997).
33. S. A. Quezada, K. S. Peggs, M. A. Curran, J. P. Allison, CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935-1945 (2006).
34. M. Jinushi, Y. Nakazaki, M. Dougan, D. R. Carrasco, M. Mihm, G. Dranoff, MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J. Clin. Invest. 117, 1902 -1913 (2007).
35. F. S. Hodi, M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. Macrae, M. Nelson, C. Canning, I. Lowy, A. Korman, D. Lautz, S. Russell, M. T. Jaklitsch, N. Ramaiya, T. C. Chen, D. Neuberg, J. P. Allison, M. C. Mihm, G. Dranoff, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A. 105, 3005-3010 (2008).
36. M. Jinushi, F. S. Hodi, G. Dranoff, Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 222, 287-298 (2008).
37. M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati, S. A. Rosenberg, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357 (2005).
38. H. Kanzler, F. J. Barrat, E. M. Hessel, R. L. Coffman, Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552-559 (2007).
39. P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte, I. Borrello, High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64, 6337-6343 (2004).
40. L. D. Harris, B. S. Kim, D. J. Mooney, Open pore biodegradable matrices formed with gas foaming. J. Biomed. Mater. Res. 42, 396-402 (1998).
41. S. Cohen, T. Yoshioka, M. Lucarelli, L. H. Hwang, R. Langer, Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8, 713-720 (1991).
42. Y. C. Huang, M. Connell, Y. Park, D. J. Mooney, K. G. Rice, Fabrication and in vitro testing of polymeric delivery system for condensed DNA. J. Biomed. Mater. Res. A 67, 1384-1392 (2003).